Modifi Bio logo 2022-07-25.png
Modifi Bio Announces Scientific Advisory Board
December 13, 2022 08:30 ET | Modifi Biosciences
NEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced its Scientific Advisory Board, with the...
With 13.1% CAGR, Breast Cancer Therapeutics Market Size to Surpass Around USD 55.27 Billion by 2027
November 08, 2022 05:36 ET | Fortune Business Insights
Pune, India, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The global breast cancer therapeutics market is set to gain impetus from the ongoing research and developments to come up with state-of-the-art drugs....
Modifi Bio logo 2022-07-25.png
Modifi Bio Receives $2.4 Million Award from National Cancer Institute to Advance Innovative Precision Oncology Platform
October 25, 2022 08:00 ET | Modifi Biosciences
NEW HAVEN, Conn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in direct DNA modification developing novel cancer therapeutics, has been selected by the National Cancer Institute...
logo.png
Cancer Therapeutics and Biotherapeutics Market Size to Surpass US$ 339.44 Bn by 2030
May 03, 2022 10:00 ET | Precedence Research
Ottawa, May 03, 2022 (GLOBE NEWSWIRE) -- The global cancer therapeutics and biotherapeutics market was estimated at US$ 161.76 billion in 2021. The government and big market participants are heavily...
Qualigen-Logo-Tag.png
Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics
January 18, 2022 09:15 ET | Qualigen Therapeutics, Inc.
Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...
full-coral-evergreen.png
Kernal Biologics Presenting Results at the 9th Annual mRNA Health Conference
November 09, 2021 02:00 ET | Kernal Biologics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve...
kernalBioLogo.JPG
Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product
July 22, 2021 08:00 ET | Kernal Biologics, Inc.
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve...
BioAffinity.jpg
bioAffinity Technologies Joins National Lung Cancer Roundtable
October 11, 2019 11:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that it has been accepted as a member of the American Cancer...
cfn_tweakedspacing.jpg
CFN Media's Exclusive Interview with Pascal Biosciences
November 08, 2018 08:30 ET | CFN Media
SEATTLE, Nov. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry,...
BioAffinity.jpg
bioAffinity Technologies Welcomes Peter S. Knight to Board of Directors
May 14, 2018 10:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, May 14, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Peter S....